Library · Metabolic & weight · Weight management and metabolic disorder treatment
Maridebart cafraglutide (AMG-133 / MariTide)
AMG-133, MariTide, AMG 133
Dual GLP-1/GIP receptor agonist (AMG-133/MariTide) from Amgen, developed in the early 2020s with an Fc fusion for extended action allowing monthly dosing. In Phase 2 trials for obesity, showing notable weight loss and metabolic improvement.
Research score 85/100. Reference only, not a dose.
- Appetite Suppression
- GLP-1 Agonist
- GIP Agonist
- Metabolic Enhancement
- Blood Sugar Control
- Weight Loss
- US status
- Investigational
- Approval
- Phase 2 Clinical Trial
- Evidence
- Antibody-peptide conjugate (GIP receptor antagonist and GLP-1 receptor agonist). Investigational for obesity with a long half-life allowing monthly dosing.
- Research score
- 85 / 100
- Indication
- Obesity/Weight Management
- Origin
- USA
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
Activates GLP-1 receptors on pancreatic beta cells and hypothalamic neurons to boost insulin release, cut glucagon, and suppress appetite, while GIP receptor activation strengthens the incretin effect; the Fc fusion extends circulation via FcRn recycling for monthly dosing.
Safety file
GI effects (nausea, vomiting, constipation) are most common, mild to moderate and dose-dependent; no unexpected safety signals or major cardiac events reported in Phase 2.
- Nausea
- Vomiting
- Injection site reactions
- Decreased appetite
- Gastrointestinal disturbances